Information  X 
Enter a valid email address

Mobeus Inc&Gwth 4 (MIG4)

  Print          Annual reports

Monday 11 January, 2021

Mobeus Inc&Gwth 4

Realisation of Investment

RNS Number : 0856L
Mobeus Income & Growth 4 VCT PLC
11 January 2021

Mobeus Income & Growth 4 VCT plc

(the "Company")


LEI:  213800IFNJ65R8AQW943



Realisation of investment in Bourn Bioscience Limited

The Company is pleased to announce the sale of its investment in Bourn Bioscience Limited ("Bourn") on 29 December 2020 to Triangle Health Care Partners 1 LP, a Canadian Fund.  The Company has received £1.50 million in cash from the sale, contributing to a realised gain over cost over the life of the investment of £0.72 million, being the equivalent of 0.86 pence per share.

Cash proceeds have been received over the life of the investment of £1.85 million, against an original cost of £1.13 million. This represents a return for the Company of 1.6 times the original investment cost and an IRR of 8.5% in the nearly seven years that this investment was held.

In isolation, the impact of this sale on the Company's latest announced NAV per share of 72.31 pence as at 30 September 2020, would be an increase of 1.33 pence per share. The Company emphasises that the increase in NAV per share from this realisation is in isolation from other changes in the Company's balance sheet, including valuation and other transaction movements in the Company's investment portfolio, that may also have affected the NAV per share since 30 September 2020.

For further information, please contact:

Mobeus Equity Partners LLP, Company Secretary 020 7024 7600


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t